Germany's Merck KGaA said on Thursday it is in late-stage talks to acquire U.S.-based SpringWorks Therapeutics for about $3.5 ...

For 2025, Merck said it still expects sales of $64.1 billion to $65.6 billion, but it lowered its adjusted earnings per share ...

Merck’s first-quarter net income increased as sales of its Keytruda cancer drug rose, but the Big Pharma company cut its 2025 ...

Merck KGaA is nearing a deal to acquire SpringWorks Therapeutics Inc., people familiar with the matter said. An announcement ...

Medical equipment supplier and pharma services outlet Thermo Fisher Scientific also said on Wednesday it estimated a $400 ...

Core inflation in Japan's capital accelerated to a two-year high in April on surging food costs, making the central bank's ...

Patients will likely eventually see higher prices and drug shortages under President Trump's plan to assess tariffs on ...

Halozyme claims Merck infringed on patents in developing a subcutaneous form of Keytruda. Elsewhere, Vanda’s challenge to an ...

Many investors are withdrawing their money from the stock market right now, but those focused on the long term know to hold ...

Merck KGaA has confirmed that it is in late-stage discussions with SpringWorks, valuing the deal at a price of around $47 per ...

Merck said the expected tariff charge primarily reflects levies between the U.S. and China, but does not account for Trump’s ...

Merck (MRK) stock rises as Summit Therapeutics (SMMT) posts latest survival data for lung cancer therapy ivonescimab ...